|
| 1 |
|
Conditions listed in this trial |
|
|
Lymphoma |
|
|
Diffuse Large Cell |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Lymphoma, Large B-Cell, Diffuse |
|
| 3 |
|
More general conditions related to this trial |
|
|
Immune System Diseases |
|
|
Immunoproliferative Disorders |
|
|
Lymphatic Diseases |
|
|
Lymphoma, B-Cell |
|
|
Lymphoma, Non-Hodgkin |
|
|
Lymphoproliferative Disorders |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
| 4 |
|
Interventions listed in this trial |
|
|
Blood draw |
|
|
Rituximab |
|
|
Cyclophosphamide |
|
|
Doxorubicin |
|
|
Vincristine |
|
|
Prednisone |
|
| 5 |
|
More general drug interventions related to this trial |
|
|
Alkylating Agents |
|
|
Anti-Inflammatory Agents |
|
|
Antibiotics, Antineoplastic |
|
|
Antimitotic Agents |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Alkylating |
|
|
Antineoplastic Agents, Hormonal |
|
|
Antineoplastic Agents, Phytogenic |
|
|
Antirheumatic Agents |
|
|
Glucocorticoids |
|
|
Hormones |
|
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
Immunologic Factors |
|
|
Immunosuppressive Agents |
|
|
Mitosis Modulators |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Myeloablative Agonists |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Therapeutic Uses |
|
|
Tubulin Modulators |
|
| 6 |
|
Sponsors listed in this trial |
|
|
Washington University School of Medicine |
|
|
BJC Foundation |
